Baird Downgrades Contineum Therapeutics to Neutral, Lowers Price Target to $14

Benzinga · 2d ago
Baird analyst Joel Beatty downgrades Contineum Therapeutics (NASDAQ:CTNM) from Outperform to Neutral and lowers the price target from $19 to $14.